SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
Status:
Completed
Trial end date:
2019-03-18
Target enrollment:
Participant gender:
Summary
The single-center, open-label Phase II study has the objective of assess the effect of MD1003
on motor and sensory conduction in patients suffering from demyelinating polyneuropathies in
15 subjects.